ArQule to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society ...
October 08 2019 - 7:00AM
Business Wire
ArQule, Inc. (Nasdaq: ARQL) today announced that it will be
presenting research on the company’s pan-AKT inhibitor, miransertib
(ARQ 092), in a poster presentation at the 2019 ASHG Annual Meeting
being held from October 15 to October 19, 2019 in Houston,
Texas.
The presentation will detail results from a preclinical study of
miransertib demonstrating its potential for treating PIK3CA-driven
vascular malformations.
Details on the presentation are as follows:
Presentation Title: PgmNr 2702/F: Miransertib (ARQ 092)
prevents the formation of PIK3CAH1047R-driven vascular
malformations in mice Abstract Number: 1920179
Presenter: Piotr Kobialka, MS, Institut d´Investigacio
Biomedica de Bellvitge Date: October 18, 2019 Poster
Viewing Time: 2:00 p.m.- 3:00 p.m. CDT Location: Exhibit
Hall-Level 1/ George R. Brown Convention Center
Additional details can be found on the meeting website. A copy
of the presentation materials can be accessed by visiting the
Publications & Presentations section of the ArQule website
after the presentation concludes.
About Miransertib Miransertib (ARQ 092) is an orally
available, selective, pan-AKT (protein kinase B) inhibitor that
potently inhibits AKT 1, 2 and 3 isoforms and binds both the active
and inactive forms of AKT which directly inhibits and prevents
membrane localization, respectively. Dysregulation of AKT has been
implicated in a variety of rare overgrowth diseases and cancers;
however, there are currently no approved inhibitors of AKT. AKT
inhibitors, either as a single agent or in combination therapy,
show significant promise in molecularly defined patient
populations. Miransertib has been granted Rare Pediatric Disease
Designation for Proteus syndrome by the U.S. Food and Drug
Administration (FDA) as well as Orphan Drug Designation by both the
FDA and European Medicines Agency. Fast Track Designation has been
granted by the FDA for PROS.
About ArQule ArQule is a biopharmaceutical company
engaged in the research and development of targeted therapeutics to
treat cancers and rare diseases. ArQule’s mission is to discover,
develop and commercialize novel small molecule drugs in areas of
high unmet need that will dramatically extend and improve the lives
of our patients. Our clinical-stage pipeline consists of four drug
candidates, all of which are in targeted, biomarker-defined patient
populations, making ArQule a leader among companies our size in
precision medicine. ArQule’s pipeline includes: ARQ 531, an orally
bioavailable, potent and reversible dual inhibitor of both wild
type and C481S-mutant BTK, in phase 1/2 for patients with B-cell
malignancies refractory to other therapeutic options; miransertib
(ARQ 092), a potent and selective inhibitor of the AKT
serine/threonine kinase, in a registrational trial with cohorts in
Proteus syndrome and PROS; ARQ 751, a next generation highly potent
and selective AKT inhibitor, in phase 1 for patients with solid
tumors with AKT1 and PI3K mutations; and derazantinib, a
multi-kinase inhibitor designed to preferentially inhibit the
fibroblast growth factor receptor (FGFR) family, in a
registrational trial for iCCA in collaboration with Basilea and
Sinovant. ArQule’s current discovery efforts are focused on the
identification and development of novel kinase inhibitors,
leveraging the Company’s proprietary library of compounds.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191008005291/en/
Corporate: Kathleen Farren Investor Relations &
Executive Assistant to the CFO ir@arqule.com
Media: Cait Williamson, Ph.D. LifeSci Public Relations
(646) 751-4366 cait@lifescipublicrelations.com
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Aug 2024 to Sep 2024
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Sep 2023 to Sep 2024